Products Olaparib was approved in the United States and EU in 2014 and in many countries in 2015 in capsule form (Lynparza). Later, film-coated tablets were also registered. Structure and properties Olaparib (C24H23FN4O3, Mr = 434.5 g/mol) Effects Olaparib (ATC L01XX46) has antitumor and cytotoxic properties. The effects are due to inhibition of PARP (poly-(ADP-ribose) … Olaparib
Products Niraparib was approved in the US and EU in 2017 and in many countries in 2018 in hard capsule form (Zejula). Structure and properties Niraparib (C19H20N4O, Mr = 320.4 g/mol) is present in the drug as niraparibtosilate monohydrate. It is a piperidine, indazole, and carboxamide derivative. Effects Niraparib (ATC L01XX54) has antitumor and cytotoxic … Niraparib
Products Talazoparib is commercially available in hard capsule form (Talzenna). It was approved in the United States in 2018 and in the EU and many countries in 2019. Structure and properties Talazoparib exists in the drug as talazoparib tosilate, a white to yellow solid. Fluorination of the drug prevents oxidative metabolism. Effects Talazoparib (ATC L01XX60) … Talazoparib
Products Rucaparib was approved in tablet form in the United States in 2016, in the EU in 2018, and in many countries in 2020 (Rubraca). Structure and properties Rucaparib (C19H18FN3O, Mr = 323.4 g/mol) is present in the drug as rucaparibcamsylate, a white to slightly yellow powder. Effects Rucaparib has antitumor and cytotoxic properties. The … Rucaparib